Bladder cancer stage II – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder cancer stage II – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment https://clinicaltrials.eu/trial/study-of-pembrolizumab-cisplatin-and-gemcitabine-for-patients-with-muscle-invasive-bladder-cancer-eligible-for-cisplatin-treatment/ Wed, 29 Apr 2026 14:25:30 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-cisplatin-and-gemcitabine-for-patients-with-muscle-invasive-bladder-cancer-eligible-for-cisplatin-treatment/ This clinical trial is focused on studying a type of bladder cancer known as muscle-invasive bladder cancer. The study is investigating the effects of a treatment called pembrolizumab, also known by its code name MK-3475, in combination with chemotherapy drugs cisplatin and gemcitabine. Pembrolizumab is a medication that helps the immune system fight cancer cells. The purpose of the study is to compare the effectiveness of pembrolizumab with chemotherapy against a placebo with chemotherapy in patients who are eligible to receive cisplatin.

Participants in the study will be randomly assigned to one of two groups. One group will receive pembrolizumab along with chemotherapy before and after surgery, while the other group will receive a placebo with the same chemotherapy regimen. The study will involve a series of treatments and follow-ups over a period of time to monitor the progress and outcomes of the treatment. The main goal is to see if the combination of pembrolizumab and chemotherapy can improve the time patients remain free from cancer events compared to the placebo group.

Throughout the study, participants will undergo various procedures, including surgery to remove the bladder and nearby lymph nodes, known as radical cystectomy and pelvic lymph node dissection. The study will also track other important outcomes, such as overall survival and the rate of complete response to the treatment. This research aims to provide valuable insights into the potential benefits of using pembrolizumab in treating muscle-invasive bladder cancer.

]]> Study on Pre-Operative Nivolumab and Relatlimab for Adults with Stage II-IIIa Muscle-Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-pre-operative-nivolumab-and-relatlimab-for-adults-with-stage-ii-iiia-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:25:25 +0000 https://clinicaltrials.eu/trial/study-on-pre-operative-nivolumab-and-relatlimab-for-adults-with-stage-ii-iiia-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying treatments for muscle-invasive urothelial cancer of the bladder, specifically in adult patients who have not yet received systemic therapy. The study involves two medications: nivolumab and relatlimab. Nivolumab is a medication that is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein. Relatlimab is also given intravenously, meaning it is injected into a vein. The purpose of the study is to evaluate the effectiveness of using nivolumab alone or in combination with relatlimab as a treatment before surgery for this type of bladder cancer.

Participants in the study will receive either nivolumab alone or a combination of nivolumab and relatlimab before undergoing surgery to remove the cancer. The study aims to determine how well these treatments work in reducing the cancer before surgery. The trial will monitor the participants’ response to the treatment and any side effects they may experience. The study will also look at how many participants are able to complete the surgery within a specific timeframe and track their overall survival and any recurrence of the cancer.

The trial is expected to run for several years, with the goal of gathering enough information to understand the potential benefits and risks of these treatments for patients with muscle-invasive urothelial cancer. By participating in this study, researchers hope to find more effective ways to treat this type of cancer and improve outcomes for patients in the future.

]]>